Horpan Tablet contains Pantoprazole 40 mg, a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive stomach acid production. Pantoprazole works by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step in acid production. This reduction in gastric acidity promotes healing of acid-related damage to the esophagus and stomach lining and alleviates symptoms such as heartburn, acid regurgitation, and epigastric pain. Horpan Tablet is typically administered orally, once daily, preferably before meals. The dosage and duration of therapy depend on the specific condition being treated and the patient's clinical response. Common side effects may include headache, diarrhea, nausea, abdominal pain, and dizziness, although it is generally well tolerated. Caution is advised in patients with liver impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and bone fractures. Horpan Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize adverse effects.